Press Releases

Investors

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arrowhead Research to Present at Two Nanomedicine-Focused Events in London
Arrowhead Research to Present at Two Nanomedicine-Focused Events in London PASADENA, Calif. – June 21, 2011 – Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced that its President and Chief
View HTML
Toggle Summary Arrowhead Research President & CEO Christopher Anzalone Featured in The Wall Street Transcript Interview
Arrowhead Research President & CEO Christopher Anzalone Featured in The Wall Street Transcript Interview PASADENA, Calif. – June 16, 2011 – Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today
View HTML
Toggle Summary Arrowhead Receives Additional 180 Day Grace Period to Comply with the NASDAQ $1.00 Minimum Bid Requirement
Arrowhead Receives Additional 180 Day Grace Period to Comply with the NASDAQ $1.00 Minimum Bid Requirement PASADENA, Calif. – June 9, 2011 – Arrowhead Research Corporation (NASDAQ: ARWR) today announced that, on June 7, 2011, it received a notification from the NASDAQ Stock Market indicating that
View HTML
Toggle Summary Arrowhead Reports Fiscal 2011 Second Quarter Financial Results
Arrowhead Reports Fiscal 2011 Second Quarter Financial Results PASADENA, Calif. – May 12, 2011 – Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced financial results for its fiscal 2011
View HTML
Toggle Summary Arrowhead Research to Report Fiscal 2011 Second Quarter Financial Results and Host Conference Call on Thursday, May 12, 2011
Arrowhead Research to Report Fiscal 2011 Second Quarter Financial Results and Host Conference Call on Thursday, May 12, 2011 PASADENA, Calif. — May 4, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR) , a nanomedicine company with development programs in oncology, obesity and regenerative
View HTML
Toggle Summary Arrowhead Research to Present at the 2011 MDB Capital Group Bright Lights Conference on May 10
Arrowhead Research to Present at the 2011 MDB Capital Group Bright Lights Conference on May 10 PASADENA, Calif. — May 3, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR) , a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced that Dr.
View HTML
Toggle Summary ARROWHEAD RESEARCH ANNOUNCES RNAI LEADER JOHN J. ROSSI, PH.D. TO JOIN CALANDO SCIENTIFIC ADVISORY BOARD
ARROWHEAD RESEARCH ANNOUNCES RNAI LEADER JOHN J. ROSSI, PH.D. TO JOIN CALANDO SCIENTIFIC ADVISORY BOARD PASADENA, Calif. — April 27, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity and regenerative medicine, today announced
View HTML
Toggle Summary ARROWHEAD RESEARCH INCREASES OWNERSHIP IN ABLARIS TO 64%
Ablaris Secures $2.9 Million to Enter Phase I Trial in Second Half 2011
View HTML
Toggle Summary Arrowhead Research to Present at the Roth Capital Partners 23rd Annual OC Growth Stock Conference on March 16
Arrowhead Research to Present at the Roth Capital Partners 23rd Annual OC Growth Stock Conference on March 16 PASADENA, Calif. — March 8, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR) , a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today
View HTML
Toggle Summary ARROWHEAD REPORTS FISCAL 2011 FIRST QUARTER FINANCIAL RESULTS
ARROWHEAD REPORTS FISCAL 2011 FIRST QUARTER FINANCIAL RESULTS PASADENA, Calif. – February 10, 2011 – Arrowhead Research Corporation (NASDAQ: ARWR) , a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced financial results for its fiscal
View HTML